DoD Breast Cancer, Innovator Award

The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.

The Innovator Award will provide these individuals with the funding and freedom to pursue

credit: Care2


their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.

Because the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative visionary individuals, rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer.

The PI should have a record of challenging the status quo, shifting paradigms by changing a field of research or approach to patient care, exhibiting high levels of creativity, and demonstrating promise for continued innovation in future work.

These rare individuals will be able to articulate a vision for ending breast cancer that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

The PI is also expected to be established in his/her field and have demonstrated success at forming and leading effective partnerships and collaborations.

To further the development of innovative individuals and spark the generation of novel ideas, applications are required to incorporate the mentoring of promising junior investigators.

Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.

This professional effort in breast cancer research can be through a combination of this award and other current support.

Individuals from other disciplines who will apply novel concepts to breast cancer are encouraged to submit.

The PI is expected to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals.

The PI’s research team must include two or more breast cancer consumer advocates.

As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization.

Their role should be independent of their employment, and they cannot be employees of any of the organizations participating in the application.

The consumer advocates should have a high level of knowledge of current breast cancer issues and the necessary background or training in breast cancer research to contribute to the project.

Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer.

Related Programs

Military Medical Research and Development

Department Of Defense


Agency: Dept. of the Army -- USAMRAA

Office:

Estimated Funding: $5,000,000


Who's Eligible





Obtain Full Opportunity Text:
https://www.grants.gov

Additional Information of Eligibility:
This opportunity is not a request for applications.

The determination not to compete is based on Departmental policy (505 DM 2.14,B.

(2) and is within the discretion of the Agency.

Full Opportunity Web Address:


Contact:


Agency Email Description:


Agency Email:
help@eBRAP.org

Date Posted:
2017-08-07

Application Due Date:
2017-12-21

Archive Date:
2018-01-20


Co-founders William Mann and David Mravyan devised the Sensimat during a mandatory project for their MBA at the Richard Ivey School of Business in Canada. Sensimat is a device that helps manage and assess pressure among wheelchair users.






More Federal Domestic Assistance Programs


State Select | U.S. Department of State | Agricultural and Rural Economic Research | Railroad Safety | Minority Economic Impact |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2024 Copyright Michael Saunders